AUA 2021: Bladder Cancer: What is New in Biomarkers? urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
Article content
Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Amphotericin B Technologies, Inc (“Amp B Tech” or the “Company”), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) (“iCo”), announced today that two presentations related to research on the effectiveness of the Company’s Oral Amphotericin B formulation (“iCo 019”) on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium –
Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsored by the Canadian Society for Pharmaceutical Sciences. (https://www.cspscanada.org/symposium-events/2021-csps-symposium/)
We apologize, but this video has failed to load.
(2)
Vancouver, British Columbia (Newsfile Corp. - May 11, 2021) - Amphotericin B Technologies, Inc ( Amp B Tech or the Company ), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) ( iCo ), announced today that two presentations related to research on the effectiveness of the Company s Oral Amphotericin B formulation ( iCo 019 ) on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium -
Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsored by the Canadian Society for Pharmaceutical Sciences. (https://www.cspscanada.org/symposium-events/2021-csps-symposium/)
William Jarosz, Chief Executive Officer of iCo and Amp B Tech, noted,